Arcticzymes Technologies ASA (AZT) - Total Assets

Latest as of December 2025: Nkr361.41 Million NOK ≈ $38.03 Million USD

Based on the latest financial reports, Arcticzymes Technologies ASA (AZT) holds total assets worth Nkr361.41 Million NOK (≈ $38.03 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check AZT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Arcticzymes Technologies ASA - Total Assets Trend (2002–2025)

This chart illustrates how Arcticzymes Technologies ASA's total assets have evolved over time, based on quarterly financial data. Check AZT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Arcticzymes Technologies ASA - Asset Composition Analysis

Current Asset Composition (December 2025)

Arcticzymes Technologies ASA's total assets of Nkr361.41 Million consist of 85.2% current assets and 14.8% non-current assets.

Asset Category Amount (NOK) % of Total Assets
Cash & Equivalents Nkr0.00 52.0%
Accounts Receivable Nkr21.88 Million 6.1%
Inventory Nkr16.16 Million 4.5%
Property, Plant & Equipment Nkr0.00 0.0%
Intangible Assets Nkr0.00 0.0%
Goodwill Nkr0.00 0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Arcticzymes Technologies ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Arcticzymes Technologies ASA.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Arcticzymes Technologies ASA's current assets represent 85.2% of total assets in 2025, an increase from 60.1% in 2002.
  • Cash Position: Cash and equivalents constituted 52.0% of total assets in 2025, up from 33.0% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2002.
  • Asset Diversification: The largest asset category is accounts receivable at 6.1% of total assets.

Arcticzymes Technologies ASA Competitors by Total Assets

Key competitors of Arcticzymes Technologies ASA based on total assets are shown below.

Company Country Total Assets
Ascendis Pharma AS
NASDAQ:ASND
USA $2.01 Billion
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $8.59 Billion
Spyre Therapeutics Inc.
NASDAQ:SYRE
USA $763.95 Million
3SBio Inc
F:83B
Germany €36.25 Billion
Soleno Therapeutics Inc
NASDAQ:SLNO
USA $608.39 Million
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
China CN¥4.48 Billion
Novavax Inc
NASDAQ:NVAX
USA $1.04 Billion
BB Biotech AG
SW:BION
Switzerland CHF2.64 Billion

Arcticzymes Technologies ASA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 16.39 17.12 16.70
Quick Ratio 15.53 16.17 16.35
Cash Ratio 0.00 10.26 0.00
Working Capital Nkr289.06 Million Nkr268.57 Million Nkr182.64 Million

Arcticzymes Technologies ASA - Advanced Valuation Insights

This section examines the relationship between Arcticzymes Technologies ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.33
Latest Market Cap to Assets Ratio 0.30
Asset Growth Rate (YoY) 5.0%
Total Assets Nkr361.41 Million
Market Capitalization $110.17 Million USD

Valuation Analysis

Below Book Valuation: The market values Arcticzymes Technologies ASA's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Arcticzymes Technologies ASA's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Arcticzymes Technologies ASA (2002–2025)

The table below shows the annual total assets of Arcticzymes Technologies ASA from 2002 to 2025.

Year Total Assets Change
2025-12-31 Nkr361.41 Million
≈ $38.03 Million
+4.98%
2024-12-31 Nkr344.26 Million
≈ $36.23 Million
+1.46%
2023-12-31 Nkr339.32 Million
≈ $35.71 Million
+6.36%
2022-12-31 Nkr319.04 Million
≈ $33.57 Million
+12.29%
2021-12-31 Nkr284.11 Million
≈ $29.90 Million
+28.03%
2020-12-31 Nkr221.91 Million
≈ $23.35 Million
+185.93%
2019-12-31 Nkr77.61 Million
≈ $8.17 Million
+14.11%
2018-12-31 Nkr68.02 Million
≈ $7.16 Million
+10.27%
2017-12-31 Nkr61.68 Million
≈ $6.49 Million
-28.13%
2016-12-31 Nkr85.83 Million
≈ $9.03 Million
-15.08%
2015-12-31 Nkr101.07 Million
≈ $10.64 Million
-9.05%
2014-12-31 Nkr111.13 Million
≈ $11.69 Million
+106.64%
2013-12-31 Nkr53.78 Million
≈ $5.66 Million
+66.83%
2012-12-31 Nkr32.24 Million
≈ $3.39 Million
-42.89%
2011-12-31 Nkr56.44 Million
≈ $5.94 Million
-18.17%
2010-12-31 Nkr68.98 Million
≈ $7.26 Million
-25.19%
2009-12-31 Nkr92.20 Million
≈ $9.70 Million
-50.90%
2008-12-31 Nkr187.77 Million
≈ $19.76 Million
-14.47%
2007-12-31 Nkr219.54 Million
≈ $23.10 Million
+77.41%
2006-12-31 Nkr123.75 Million
≈ $13.02 Million
-11.98%
2005-12-31 Nkr140.59 Million
≈ $14.79 Million
+140.00%
2004-12-31 Nkr58.58 Million
≈ $6.16 Million
-10.55%
2003-12-31 Nkr65.49 Million
≈ $6.89 Million
+757.74%
2002-12-31 Nkr7.63 Million
≈ $803.39K
--

About Arcticzymes Technologies ASA

OL:AZT Norway Biotechnology
Market Cap
$110.17 Million
Nkr1.05 Billion NOK
Market Cap Rank
#18898 Global
#165 in Norway
Share Price
Nkr20.50
Change (1 day)
+1.99%
52-Week Range
Nkr16.15 - Nkr30.90
All Time High
Nkr111.00
About

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more